Literature DB >> 19858067

Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms.

Emilija Makaji1, Cristina S Trambitas, Pamela Shen, Alison C Holloway, Denis J Crankshaw.   

Abstract

We have evaluated the use of a panel of six fluorogenic cytochrome P450 (CYP) substrates as a potential tool for rapid screening for global changes in CYP activity in rats under different physiological conditions. The biotransformation of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC), 7-benzyloxy-4-(trifluoromethyl)-coumarin, 7-benzyloxyquinoline, 3-cyano-7-ethoxycoumarin, 7-methoxy-4-(trifluoromethyl)-coumarin, and 7-ethoxy-4-trifluoromethyl-coumarin by microsomes from adult male rat liver were characterized, their sensitivities to 15 putative inhibitors were determined and compared to similar experiments using nine different complementary DNA (cDNA)-expressed rat CYPs. Inhibitory profiles of the substrates in microsomes were different from each other, with some overlap, suggesting that each substrate is to some extent biotransformed by a different CYP isoform. Ketoconazole and clotrimazole were nonselective inhibitors, while ticlopidine selectively inhibited biotransformation of AMMC. CYP2A1 did not biotransform any of the substrates, and CYP2E1 was insensitive to all the inhibitors tested. Some inhibitors did not affect the biotransformation of the fluorogenic substrates by cDNA-expressed isoforms as predicted by their effects on conventional substrates, e.g., chlorzoxazone and diethyldithiocarbamate were inactive against CYP2E1, and CYP2C6 was not inhibited by sulfaphenazole. When results in microsomes and cDNA-expressed CYPs were compared, only the majority of the biotransformation of AMMC by microsomes could be assigned with full confidence to a specific CYP isoform, namely CYP2D2. Nevertheless, different inhibitory profiles of the substrates indicate that the panel will be useful for rapid functional quantification of global CYP activity in rats under different experimental conditions. Our results also demonstrate the inappropriateness of extrapolating inhibitory data between conventional and fluorogenic CYP substrates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858067     DOI: 10.1093/toxsci/kfp255

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  5 in total

1.  Inhibition of cytochrome P450 2B4 by environmentally persistent free radical-containing particulate matter.

Authors:  James R Reed; Albert Leo N dela Cruz; Slawo M Lomnicki; Wayne L Backes
Journal:  Biochem Pharmacol       Date:  2015-03-24       Impact factor: 5.858

2.  Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.

Authors:  Karen M McCammon; Satya P Panda; Chuanwu Xia; Jung-Ja P Kim; Daniela Moutinho; Michel Kranendonk; Richard J Auchus; Eileen M Lafer; Debashis Ghosh; Pavel Martasek; Rekha Kar; Bettie Sue Masters; Linda J Roman
Journal:  J Biol Chem       Date:  2016-08-05       Impact factor: 5.157

3.  Environmentally persistent free radicals inhibit cytochrome P450 activity in rat liver microsomes.

Authors:  James R Reed; George F Cawley; Taylor G Ardoin; Barry Dellinger; Slawomir M Lomnicki; Farhana Hasan; Lucy W Kiruri; Wayne L Backes
Journal:  Toxicol Appl Pharmacol       Date:  2014-04-05       Impact factor: 4.219

4.  Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.

Authors:  Sumanta Kumar Goswami; Bora Inceoglu; Jun Yang; Debin Wan; Sean D Kodani; Carlos Antonio Trindade da Silva; Christophe Morisseau; Bruce D Hammock
Journal:  Toxicol Appl Pharmacol       Date:  2015-11-10       Impact factor: 4.219

5.  In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole.

Authors:  Seong-Wook Seo; Jin Woo Park; Dong-Gyun Han; Ji-Min Kim; Sanghyun Kim; Taeuk Park; Kyung-Hwa Kang; Min Hye Yang; In-Soo Yoon
Journal:  Pharmaceutics       Date:  2019-12-11       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.